CA2869145A1 - Pharmaceutical compositions for combination therapy - Google Patents
Pharmaceutical compositions for combination therapy Download PDFInfo
- Publication number
- CA2869145A1 CA2869145A1 CA 2869145 CA2869145A CA2869145A1 CA 2869145 A1 CA2869145 A1 CA 2869145A1 CA 2869145 CA2869145 CA 2869145 CA 2869145 A CA2869145 A CA 2869145A CA 2869145 A1 CA2869145 A1 CA 2869145A1
- Authority
- CA
- Canada
- Prior art keywords
- acceptable salt
- tetrabenazine
- pharmaceutically acceptable
- pridopidine
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 48
- 238000002648 combination therapy Methods 0.000 title description 14
- MKJIEFSOBYUXJB-HOCLYGCPSA-N (3S,11bS)-9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one Chemical compound C1CN2C[C@H](CC(C)C)C(=O)C[C@H]2C2=C1C=C(OC)C(OC)=C2 MKJIEFSOBYUXJB-HOCLYGCPSA-N 0.000 claims abstract description 292
- 229960005333 tetrabenazine Drugs 0.000 claims abstract description 290
- YGKUEOZJFIXDGI-UHFFFAOYSA-N pridopidine Chemical compound C1CN(CCC)CCC1C1=CC=CC(S(C)(=O)=O)=C1 YGKUEOZJFIXDGI-UHFFFAOYSA-N 0.000 claims abstract description 253
- 229950003764 pridopidine Drugs 0.000 claims abstract description 244
- 230000000694 effects Effects 0.000 claims abstract description 116
- 238000011282 treatment Methods 0.000 claims abstract description 86
- 208000016285 Movement disease Diseases 0.000 claims abstract description 65
- 208000023105 Huntington disease Diseases 0.000 claims abstract description 30
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims abstract description 22
- 208000000323 Tourette Syndrome Diseases 0.000 claims abstract description 22
- 230000001603 reducing effect Effects 0.000 claims abstract description 6
- 150000003839 salts Chemical class 0.000 claims description 204
- 238000000034 method Methods 0.000 claims description 54
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 29
- 208000035475 disorder Diseases 0.000 claims description 25
- 208000008589 Obesity Diseases 0.000 claims description 24
- 235000020824 obesity Nutrition 0.000 claims description 24
- 208000016620 Tourette disease Diseases 0.000 claims description 17
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 12
- 238000002560 therapeutic procedure Methods 0.000 claims description 10
- 230000033001 locomotion Effects 0.000 claims description 9
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 6
- 206010034010 Parkinsonism Diseases 0.000 claims description 6
- 206010008748 Chorea Diseases 0.000 claims description 5
- 208000012601 choreatic disease Diseases 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 208000001431 Psychomotor Agitation Diseases 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 3
- 206010001497 Agitation Diseases 0.000 claims description 2
- 206010001540 Akathisia Diseases 0.000 claims description 2
- 208000019505 Deglutition disease Diseases 0.000 claims description 2
- 206010038743 Restlessness Diseases 0.000 claims description 2
- 206010039897 Sedation Diseases 0.000 claims description 2
- 208000032140 Sleepiness Diseases 0.000 claims description 2
- 206010041349 Somnolence Diseases 0.000 claims description 2
- 238000013019 agitation Methods 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 230000000977 initiatory effect Effects 0.000 claims description 2
- 230000036280 sedation Effects 0.000 claims description 2
- 230000000737 periodic effect Effects 0.000 claims 1
- 230000003291 dopaminomimetic effect Effects 0.000 abstract description 8
- 239000003381 stabilizer Substances 0.000 abstract description 8
- 230000001225 therapeutic effect Effects 0.000 abstract description 7
- 230000002411 adverse Effects 0.000 abstract description 6
- 102000009659 Vesicular Monoamine Transport Proteins Human genes 0.000 abstract description 2
- 108010020033 Vesicular Monoamine Transport Proteins Proteins 0.000 abstract description 2
- 239000003112 inhibitor Substances 0.000 abstract description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 145
- CFFZDZCDUFSOFZ-UHFFFAOYSA-N 3,4-Dihydroxy-phenylacetic acid Chemical compound OC(=O)CC1=CC=C(O)C(O)=C1 CFFZDZCDUFSOFZ-UHFFFAOYSA-N 0.000 description 105
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 98
- 229960003878 haloperidol Drugs 0.000 description 72
- 230000006742 locomotor activity Effects 0.000 description 56
- 229960003638 dopamine Drugs 0.000 description 49
- 241001465754 Metazoa Species 0.000 description 45
- 150000001875 compounds Chemical class 0.000 description 42
- 239000003981 vehicle Substances 0.000 description 42
- 239000003814 drug Substances 0.000 description 31
- 210000005153 frontal cortex Anatomy 0.000 description 30
- 108020004999 messenger RNA Proteins 0.000 description 29
- 230000002829 reductive effect Effects 0.000 description 29
- 229940079593 drug Drugs 0.000 description 25
- 230000003993 interaction Effects 0.000 description 25
- 230000014509 gene expression Effects 0.000 description 24
- 210000001577 neostriatum Anatomy 0.000 description 24
- 102000004980 Dopamine D2 Receptors Human genes 0.000 description 23
- 108090001111 Dopamine D2 Receptors Proteins 0.000 description 23
- 238000002474 experimental method Methods 0.000 description 23
- 241000700159 Rattus Species 0.000 description 22
- 108090000623 proteins and genes Proteins 0.000 description 20
- 230000003542 behavioural effect Effects 0.000 description 19
- 238000007920 subcutaneous administration Methods 0.000 description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 17
- 230000002265 prevention Effects 0.000 description 17
- 231100000673 dose–response relationship Toxicity 0.000 description 16
- 230000009467 reduction Effects 0.000 description 16
- 101150016797 arc gene Proteins 0.000 description 15
- 230000005764 inhibitory process Effects 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- 230000037361 pathway Effects 0.000 description 15
- 230000007423 decrease Effects 0.000 description 14
- 239000011780 sodium chloride Substances 0.000 description 14
- 230000002269 spontaneous effect Effects 0.000 description 13
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 12
- 239000008186 active pharmaceutical agent Substances 0.000 description 12
- 239000002552 dosage form Substances 0.000 description 12
- 239000008103 glucose Substances 0.000 description 12
- QRMZSPFSDQBLIX-UHFFFAOYSA-N homovanillic acid Chemical compound COC1=CC(CC(O)=O)=CC=C1O QRMZSPFSDQBLIX-UHFFFAOYSA-N 0.000 description 12
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 12
- 108091006629 SLC13A2 Proteins 0.000 description 11
- 230000003137 locomotive effect Effects 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 241000124008 Mammalia Species 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 208000012661 Dyskinesia Diseases 0.000 description 9
- 208000000269 Hyperkinesis Diseases 0.000 description 9
- 239000002299 complementary DNA Substances 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 230000003247 decreasing effect Effects 0.000 description 8
- 230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 description 8
- 230000000144 pharmacologic effect Effects 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 230000000692 anti-sense effect Effects 0.000 description 7
- 230000005540 biological transmission Effects 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 230000001054 cortical effect Effects 0.000 description 7
- 210000002569 neuron Anatomy 0.000 description 7
- 238000003753 real-time PCR Methods 0.000 description 7
- 208000015592 Involuntary movements Diseases 0.000 description 6
- 230000008485 antagonism Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- DIVQKHQLANKJQO-UHFFFAOYSA-N 3-methoxytyramine Chemical compound COC1=CC(CCN)=CC=C1O DIVQKHQLANKJQO-UHFFFAOYSA-N 0.000 description 5
- 206010013710 Drug interaction Diseases 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000001722 neurochemical effect Effects 0.000 description 5
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 230000000946 synaptic effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000003643 water by type Substances 0.000 description 5
- 108010072220 Cyclophilin A Proteins 0.000 description 4
- 101150049660 DRD2 gene Proteins 0.000 description 4
- 229940127333 Dopamine D2 Antagonists Drugs 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 102100034539 Peptidyl-prolyl cis-trans isomerase A Human genes 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 238000000137 annealing Methods 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000036425 denaturation Effects 0.000 description 4
- 238000004925 denaturation Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 229960001484 edetic acid Drugs 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 238000011533 pre-incubation Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- -1 (SS Chemical compound 0.000 description 3
- MKJIEFSOBYUXJB-UHFFFAOYSA-N 9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one Chemical compound C1CN2CC(CC(C)C)C(=O)CC2C2=C1C=C(OC)C(OC)=C2 MKJIEFSOBYUXJB-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 102000004357 Transferases Human genes 0.000 description 3
- 108090000992 Transferases Proteins 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 230000003579 anti-obesity Effects 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000000442 dopamine 2 receptor blocking agent Substances 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000007659 motor function Effects 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 230000021542 voluntary musculoskeletal movement Effects 0.000 description 3
- DUUGKQCEGZLZNO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Chemical compound C1=C(O)C=C2C(CC(=O)O)=CNC2=C1 DUUGKQCEGZLZNO-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 102100033647 Activity-regulated cytoskeleton-associated protein Human genes 0.000 description 2
- 101710177131 Activity-regulated cytoskeleton-associated protein Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010067671 Disease complication Diseases 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 102000004076 Dopamine D1 Receptors Human genes 0.000 description 2
- 108090000511 Dopamine D1 Receptors Proteins 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 2
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- KSRGADMGIRTXAF-UHFFFAOYSA-N a-Methyldopamine Chemical compound CC(N)CC1=CC=C(O)C(O)=C1 KSRGADMGIRTXAF-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000001090 anti-dopaminergic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000011278 co-treatment Methods 0.000 description 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
- 230000000779 depleting effect Effects 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 238000000835 electrochemical detection Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000010304 firing Methods 0.000 description 2
- 230000003371 gabaergic effect Effects 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- YQOKLYTXVFAUCW-UHFFFAOYSA-N guanidine;isothiocyanic acid Chemical compound N=C=S.NC(N)=N YQOKLYTXVFAUCW-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002197 limbic effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 210000001103 thalamus Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 229940025158 xenazine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 description 1
- MKIBUMXSJANYQB-HNNXBMFYSA-N (2s)-2-(3-methylsulfonylphenyl)-1-propylpiperidine Chemical compound CCCN1CCCC[C@H]1C1=CC=CC(S(C)(=O)=O)=C1 MKIBUMXSJANYQB-HNNXBMFYSA-N 0.000 description 1
- QYAPHLRPFNSDNH-MRFRVZCGSA-N (4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O QYAPHLRPFNSDNH-MRFRVZCGSA-N 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- JTTIOYHBNXDJOD-UHFFFAOYSA-N 2,4,6-triaminopyrimidine Chemical compound NC1=CC(N)=NC(N)=N1 JTTIOYHBNXDJOD-UHFFFAOYSA-N 0.000 description 1
- UDGUGZTYGWUUSG-UHFFFAOYSA-N 4-[4-[[2,5-dimethoxy-4-[(4-nitrophenyl)diazenyl]phenyl]diazenyl]-n-methylanilino]butanoic acid Chemical compound COC=1C=C(N=NC=2C=CC(=CC=2)N(C)CCCC(O)=O)C(OC)=CC=1N=NC1=CC=C([N+]([O-])=O)C=C1 UDGUGZTYGWUUSG-UHFFFAOYSA-N 0.000 description 1
- UTBULQCHEUWJNV-UHFFFAOYSA-N 4-phenylpiperidine Chemical class C1CNCCC1C1=CC=CC=C1 UTBULQCHEUWJNV-UHFFFAOYSA-N 0.000 description 1
- ASXGJMSKWNBENU-UHFFFAOYSA-N 8-OH-DPAT Chemical compound C1=CC(O)=C2CC(N(CCC)CCC)CCC2=C1 ASXGJMSKWNBENU-UHFFFAOYSA-N 0.000 description 1
- GEICAQNIOJFRQN-UHFFFAOYSA-N 9-aminomethyl-9,10-dihydroanthracene Chemical compound C1=CC=C2C(CN)C3=CC=CC=C3CC2=C1 GEICAQNIOJFRQN-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 1
- ANUJDLRACOBTTB-UHFFFAOYSA-N C1(CCC1)NC=1C2=C(N=CN=1)SC1=C2CCCC1 Chemical compound C1(CCC1)NC=1C2=C(N=CN=1)SC1=C2CCCC1 ANUJDLRACOBTTB-UHFFFAOYSA-N 0.000 description 1
- 208000009132 Catalepsy Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108010068682 Cyclophilins Proteins 0.000 description 1
- 102000001493 Cyclophilins Human genes 0.000 description 1
- 206010011953 Decreased activity Diseases 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101001094518 Escherichia coli Ribonuclease H Proteins 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010072051 Glatiramer Acetate Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000724418 Homo sapiens Neutral amino acid transporter B(0) Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 108700002232 Immediate-Early Genes Proteins 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- PKVZBNCYEICAQP-UHFFFAOYSA-N Mecamylamine hydrochloride Chemical compound Cl.C1CC2C(C)(C)C(NC)(C)C1C2 PKVZBNCYEICAQP-UHFFFAOYSA-N 0.000 description 1
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229940099433 NMDA receptor antagonist Drugs 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 102100028267 Neutral amino acid transporter B(0) Human genes 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- YNYAYWLBAHXHLL-UHFFFAOYSA-N Normetanephrine Chemical compound COC1=CC(C(O)CN)=CC=C1O YNYAYWLBAHXHLL-UHFFFAOYSA-N 0.000 description 1
- YNYAYWLBAHXHLL-MRVPVSSYSA-N Normetanephrine Natural products COC1=CC([C@H](O)CN)=CC=C1O YNYAYWLBAHXHLL-MRVPVSSYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010047853 Waxy flexibility Diseases 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 210000004727 amygdala Anatomy 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 101150010487 are gene Proteins 0.000 description 1
- 229960004372 aripiprazole Drugs 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 230000008406 drug-drug interaction Effects 0.000 description 1
- 229950005627 embonate Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229950011470 enantate Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 210000001222 gaba-ergic neuron Anatomy 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229910021397 glassy carbon Inorganic materials 0.000 description 1
- 229960003776 glatiramer acetate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 210000001362 glutamatergic neuron Anatomy 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 230000001660 hyperkinetic effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000008986 metabolic interaction Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 230000001730 monoaminergic effect Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 229960005027 natalizumab Drugs 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 210000001009 nucleus accumben Anatomy 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 210000001010 olfactory tubercle Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- YZTJYBJCZXZGCT-UHFFFAOYSA-N phenylpiperazine Chemical class C1CNCCN1C1=CC=CC=C1 YZTJYBJCZXZGCT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 230000009290 primary effect Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000003368 psychostimulant agent Substances 0.000 description 1
- 210000002763 pyramidal cell Anatomy 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229940075554 sorbate Drugs 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 230000002739 subcortical effect Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 230000015883 synaptic transmission, dopaminergic Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261620203P | 2012-04-04 | 2012-04-04 | |
| US61/620,203 | 2012-04-04 | ||
| US201261625192P | 2012-04-17 | 2012-04-17 | |
| US61/625,192 | 2012-04-17 | ||
| US201361783730P | 2013-03-14 | 2013-03-14 | |
| US61/783,730 | 2013-03-14 | ||
| PCT/US2013/035124 WO2013152105A1 (en) | 2012-04-04 | 2013-04-03 | Pharmaceutical compositions for combination therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2869145A1 true CA2869145A1 (en) | 2013-10-10 |
Family
ID=49292803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2869145 Abandoned CA2869145A1 (en) | 2012-04-04 | 2013-04-03 | Pharmaceutical compositions for combination therapy |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20130267552A1 (enExample) |
| EP (1) | EP2844346B1 (enExample) |
| JP (1) | JP6177875B2 (enExample) |
| KR (1) | KR20150013476A (enExample) |
| CN (1) | CN104470585A (enExample) |
| AU (1) | AU2013243461A1 (enExample) |
| BR (1) | BR112014024672A8 (enExample) |
| CA (1) | CA2869145A1 (enExample) |
| EA (1) | EA027748B1 (enExample) |
| ES (1) | ES2776678T3 (enExample) |
| HK (1) | HK1206297A1 (enExample) |
| IL (1) | IL234831B (enExample) |
| MX (1) | MX2014011971A (enExample) |
| NZ (1) | NZ630560A (enExample) |
| WO (1) | WO2013152105A1 (enExample) |
| ZA (1) | ZA201407726B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| DK2146961T3 (da) * | 2007-04-12 | 2014-04-28 | Ivax Int Gmbh | N-oxid- og/eller di-N-oxidderivater af dopaminreceptorstabilisatorer/modulatorer udvisende forbedrede cardiovaskulære bivirkningsprofiler |
| BR112013005125A2 (pt) | 2010-09-03 | 2016-08-16 | Ivax Int Gmbh | deuterados análogos dos pridopidine úteis como estabilizadores dopaminérgicos |
| CA2847736A1 (en) | 2011-09-07 | 2013-03-14 | IVAX International GmbH | A new polymorphic form of pridopidine hydrochloride |
| MX347209B (es) | 2011-12-08 | 2017-04-19 | Teva Pharmaceuticals Int Gmbh | La sal de bromhidrato de pridopidina. |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| JP2016523862A (ja) | 2013-06-21 | 2016-08-12 | テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ | ハンチントン病を治療するための高用量プリドピジンの使用 |
| PL3096759T3 (pl) * | 2014-01-22 | 2022-06-13 | Prilenia Neurotherapeutics Ltd. | Preparaty pridopidyny o zmodyfikowanym uwalnianiu |
| MX386901B (es) * | 2014-04-25 | 2025-03-19 | Chugai Pharmaceutical Co Ltd | Formulacion que contiene una gran cantidad de compuesto tetraciclico. |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| CA2970799A1 (en) | 2014-12-22 | 2016-06-30 | Teva Pharmaceuticals International Gmbh | L-tartrate salt of pridopidine |
| US11471449B2 (en) | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
| HUE060353T2 (hu) | 2015-02-25 | 2023-02-28 | Prilenia Neurotherapeutics Ltd | Pridopidin alkalmazása memória javítására |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| JP7034488B2 (ja) | 2016-02-24 | 2022-03-14 | プリレニア・ニューロセラピューティクス・エルティーディー | プリドピジンを使用する神経変性眼疾患の治療 |
| HUE071008T2 (hu) | 2016-08-24 | 2025-07-28 | Prilenia Neurotherapeutics Ltd | Pridopidin alkalmazása mûködési hanyatlás kezelésére |
| CA3035099C (en) | 2016-08-24 | 2023-01-17 | Prilenia Therapeutics Development Ltd. | Use of pridopidine for treating dystonias |
| US12102627B2 (en) | 2016-09-16 | 2024-10-01 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating rett syndrome |
| CA3036984C (en) | 2016-09-16 | 2023-07-18 | Prilenia Therapeutics Development Ltd. | Use of pridopidine for treating rett syndrome |
| IL268125B2 (en) | 2017-01-20 | 2023-04-01 | Prilenia Neurotherapeutics Ltd | Pridopidine for the treatment of fragile x syndrome |
| US11253594B2 (en) | 2017-07-07 | 2022-02-22 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Drug combinations for protecting against neuronal cell death |
| EP3664787B1 (en) | 2017-07-20 | 2022-07-20 | Neurolixis | Use of selective serotonin 5-ht1a receptor agonists for treating side-effects of vmat inhibitors |
| HUE061505T2 (hu) | 2017-08-14 | 2023-07-28 | Prilenia Neurotherapeutics Ltd | Módszer amyothrophiás lateralsclerosis kezelésére pridopidinnel |
| EA202090542A1 (ru) | 2017-08-30 | 2020-06-08 | Приления Ньюротерапьютикс Лтд. | Высококонцентрированные лекарственные формы придопидина |
| WO2020110128A1 (en) * | 2018-11-29 | 2020-06-04 | Prilenia Neurotherapeutics Ltd. | Combination of pridopidine and an additional therapeutic agent for treating drug induced dyskinesia |
| AU2018329628B2 (en) * | 2017-09-08 | 2021-04-22 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| US12036213B2 (en) | 2017-09-08 | 2024-07-16 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| JP2021510971A (ja) * | 2018-01-17 | 2021-04-30 | ヒルシュマン カー コミュニケーション ゲゼルシャフト ミット ベシュレンクテル ハフツングＨｉｒｓｃｈｍａｎｎ Ｃａｒ Ｃｏｍｍｕｎｉｃａｔｉｏｎ ＧｍｂＨ | 受信機システムから遠隔にあるｌｔｅモジュール |
| AU2019261403B2 (en) * | 2018-04-25 | 2025-05-15 | Shinkei Therapeutics, Inc. | Tetrabenazine transdermal delivery device |
| CN113395964A (zh) | 2019-02-04 | 2021-09-14 | 普瑞尼亚神经治疗有限公司 | 用于帕金森氏病和与帕金森症相关的其它疾病的低剂量普利多匹定 |
| IL297932A (en) * | 2020-05-04 | 2023-01-01 | Prilenia Neurotherapeutics Ltd | Treatment of viral infection, disease or disorder using a selective s1r agonist |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB850662A (en) | 1956-10-22 | 1960-10-05 | Parke Davis & Co | Substituted piperazines and processes for their production |
| BE662455A (enExample) | 1964-04-14 | |||
| GB1060160A (en) | 1964-08-05 | 1967-03-01 | Allen & Hanburys Ltd | 4-phenylpiperidine derivatives |
| US3539573A (en) | 1967-03-22 | 1970-11-10 | Jean Schmutz | 11-basic substituted dibenzodiazepines and dibenzothiazepines |
| ZA7546B (en) | 1974-01-21 | 1976-08-25 | Parke Davis & Co | New antibacterial amide compounds and methods for their production |
| US4048314A (en) | 1974-12-17 | 1977-09-13 | Delmar Chemicals Limited | Morpholino containing 4-arylpiperidine derivatives |
| US4202898A (en) | 1978-06-05 | 1980-05-13 | Synthelabo | Method of treating anxiety and depression |
| US4267328A (en) | 1978-08-01 | 1981-05-12 | Synthelabo | 1-Phenylpiperazines |
| US4333942A (en) | 1979-08-03 | 1982-06-08 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Anti-depressant and analgesic 4-phenoxypiperidines |
| US4518712A (en) | 1980-06-30 | 1985-05-21 | Taiho Pharmaceutical Company Limited | Piperazine derivative and analgesic composition containing the same |
| GB2083476B (en) | 1980-09-12 | 1984-02-08 | Wyeth John & Brother Ltd | Heterocyclic compounds |
| FR2501506A1 (fr) | 1981-03-11 | 1982-09-17 | Sanofi Sa | Compositions pharmaceutiques a action anorexigene contenant des derives de la tetrahydropyridine |
| US4415736A (en) | 1981-12-28 | 1983-11-15 | E. I. Du Pont De Nemours & Co. | Certain tetrahydropyridine intermediates |
| US4485109A (en) | 1982-05-07 | 1984-11-27 | E. I. Du Pont De Nemours And Company | 4-Aryl-4-piperidinecarbinols |
| EP0094159B1 (en) | 1982-05-10 | 1990-03-14 | Takeda Chemical Industries, Ltd. | Dihydropyridine derivatives, their production and use |
| US4504660A (en) | 1982-07-06 | 1985-03-12 | American Home Products Corporation | Process for the production of 2,6-diaminobenzonitrile derivatives |
| DE3306964A1 (de) | 1983-02-28 | 1984-09-06 | Boehringer Ingelheim KG, 6507 Ingelheim | Neues n-arylpiperazin und verfahren zu seiner herstellung |
| HU198454B (en) | 1987-12-14 | 1989-10-30 | Richter Gedeon Vegyeszet | Process for production of new derivatives of tetrahydrospiridin and medical compositions containing these compounds |
| FR2639226B1 (fr) | 1988-11-18 | 1993-11-05 | Sanofi | Utilisation de trifluoromethylphenyltetrahydropyridines pour la preparation de medicaments destines a combattre les troubles anxio-depressifs |
| CA2071897A1 (en) | 1989-12-28 | 1991-06-29 | Richard A. Glennon | Sigma receptor ligands and the use thereof |
| AU653837B2 (en) | 1991-04-17 | 1994-10-13 | Pharmacia & Upjohn Company | Substituted phenylazacycloalkanes as CNS agents |
| PT100639A (pt) | 1991-06-27 | 1993-09-30 | Univ Virginia Commonwealth | Metodo para o tratamento terapeutico com compostos que sao ligandos ao receptor sigma e compostos ai utilizados, nomeadamente derivados fenilalquil-amina, aminotetralina,piperazina e piperidina |
| NZ240863A (en) | 1991-09-11 | 1995-04-27 | Mcneilab Inc | Substituted 4-aryl piperidine and 4-aryl piperazine derivatives, preparation and pharmaceutical compositions thereof |
| ES2162792T3 (es) | 1991-09-18 | 2002-01-16 | Glaxo Group Ltd | Derivados de benzanilida como antagonistas de 5-ht1d. |
| GB9119932D0 (en) | 1991-09-18 | 1991-10-30 | Glaxo Group Ltd | Chemical compounds |
| GB9119920D0 (en) | 1991-09-18 | 1991-10-30 | Glaxo Group Ltd | Chemical compounds |
| US5502050A (en) | 1993-11-29 | 1996-03-26 | Cornell Research Foundation, Inc. | Blocking utilization of tetrahydrobiopterin to block induction of nitric oxide synthesis |
| IL112099A (en) | 1993-12-23 | 1999-07-14 | Ortho Pharma Corp | N-oxides of 4-arylpiperazines and 4-arylpiperidines and pharmaceutical compositions containing them |
| CA2144669A1 (en) | 1994-03-29 | 1995-09-30 | Kozo Akasaka | Biphenyl derivatives |
| ZA954688B (en) | 1994-06-08 | 1996-01-29 | Lundbeck & Co As H | Serotonin 5-HT1A and dopamin D2 receptor ligands |
| AU6470096A (en) | 1995-07-19 | 1997-02-18 | Yoshitomi Pharmaceutical Industries, Ltd. | Fused triazole compounds |
| ZA9610745B (en) | 1995-12-22 | 1997-06-24 | Warner Lambert Co | 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists |
| HUP9904335A3 (en) | 1996-07-22 | 2001-07-30 | Daiichi Asubio Pharma Co Ltd | Arylpiperidinol and arylpiperidine derivatives and drugs containing the same |
| US5892041A (en) | 1996-08-12 | 1999-04-06 | Neurogen Corporation | Fused indolecarboxamides: dopamine receptor subtype specific ligands |
| DE19637237A1 (de) | 1996-09-13 | 1998-03-19 | Merck Patent Gmbh | Piperazin-Derivate |
| CA2288172A1 (en) | 1997-04-18 | 1998-10-29 | Smithkline Beecham P.L.C. | A bicyclic aryl or a bicyclic heterocyclic ring containing compounds having a combined 5ht1a, 5ht1b and 5ht1d receptor antagonistic activity |
| EE200200633A (et) | 1997-06-10 | 2003-02-17 | Synthon B.V. | Meetod triasendatud 4-fenüülpiperidiinühendi soola ja aluse vormide saamiseks, saadud soola ja aluse vormid |
| SE9702716D0 (sv) | 1997-07-15 | 1997-07-15 | Ross Nicholas Waters | Substituted phenylazacycloalkanes in the treatment of cognitive disorders |
| ATE330930T1 (de) * | 1997-08-07 | 2006-07-15 | Fujimoto Brothers Co Ltd | Neue ethylaminderivate |
| US6232326B1 (en) | 1998-07-14 | 2001-05-15 | Jodi A. Nelson | Treatment for schizophrenia and other dopamine system dysfunctions |
| DE69912635T2 (de) | 1998-11-23 | 2004-05-13 | Sepracor Inc., Marlborough | Olanzapin-n-oxide enthaltende pharmaceutische zusammensetzungen |
| IL146403A0 (en) | 1999-06-22 | 2002-07-25 | Neurosearch As | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds |
| AU6386700A (en) | 1999-07-30 | 2001-02-19 | University Of Kentucky Research Foundation, The | Cis-2,6-disubstituted piperidines for the treatment of psychostimulant abuse and withdrawal, eating disorders, and central nervous system diseases and pathologies |
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| SE9904723D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission II |
| SE9904724D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| EP1313477A4 (en) | 2000-07-15 | 2004-03-03 | Smithkline Beecham Corp | COMPILATIONS AND METHODS |
| ATE301652T1 (de) | 2001-01-23 | 2005-08-15 | Lilly Co Eli | Piperazinderivate als agonisten des melanocortin- rezeptors |
| SE0200301D0 (sv) | 2002-02-01 | 2002-02-01 | Axon Biochemicals Bv | Thio-carbostyril derivative |
| US20050004164A1 (en) | 2003-04-30 | 2005-01-06 | Caggiano Thomas J. | 2-Cyanopropanoic acid amide and ester derivatives and methods of their use |
| US7160888B2 (en) | 2003-08-22 | 2007-01-09 | Warner Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
| SE0401465D0 (sv) | 2004-06-08 | 2004-06-08 | Carlsson A Research Ab | New substituted piperdines as modulators of dopamine neurotransmission |
| ATE469885T1 (de) | 2004-06-08 | 2010-06-15 | Nsab Af Neurosearch Sweden Ab | Neue disubstituierte phenylpiperidine und piperazine als modulatoren der dopamin- neurotransmission |
| DE602005017784D1 (de) | 2004-06-08 | 2009-12-31 | Nsab, Filial Af Neurosearch Sweden Ab | Neue disubstituierte phenylpiperidine als modulatoren der dopamin- und serotoninneurotransmission |
| US7851629B2 (en) | 2004-06-08 | 2010-12-14 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission |
| EP1796669B1 (en) | 2004-10-01 | 2010-09-22 | Merck Sharp & Dohme Corp. | Aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| NZ555095A (en) | 2004-10-13 | 2010-07-30 | Nsab Af Neurosearch Sweden Ab | Process for the synthesis of 4-(3-sulfonylphenyl)-piperidines |
| DK1802573T3 (en) | 2004-10-13 | 2016-12-19 | Teva Pharmaceuticals Int Gmbh | METHOD OF SYNTHESIS OF 4- (3-METHANSULPHONYLPHENYL) -1-N-PROPYL-PIPERIDINE. |
| JP2009504799A (ja) | 2005-08-22 | 2009-02-05 | ソルベイ・フアーマシユーチカルズ・ベー・ブイ | ピペラジンおよびピペリジン誘導体のプロドラッグとしてのｎ−オキシド |
| SE529246C2 (sv) | 2005-10-13 | 2007-06-12 | Neurosearch Sweden Ab | Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission |
| US20080269286A1 (en) | 2005-12-07 | 2008-10-30 | Clas Sonesson | Disubstituted Phenylpiperidines as Modulators of Cortical Catecholaminergic Neurotransmission |
| CN101432279A (zh) | 2006-05-02 | 2009-05-13 | 索尔瓦药物有限公司 | 吡啶基甲基哌嗪和吡啶基甲基哌啶衍生物的n-氧化物 |
| WO2007129066A1 (en) | 2006-05-05 | 2007-11-15 | Astex Therapeutics Limited | 4- (2,6-dichloro-benzoylamino) -1h-pyrazole-3-carboxylic acid (1-methanesulphonyl-piperidin-4-yl) -amide for the treatment of cancer |
| EP1961742A1 (en) | 2007-02-22 | 2008-08-27 | Novartis AG | compounds of formula (I) as serine protease inhibitors |
| US20100204258A1 (en) * | 2007-03-12 | 2010-08-12 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for modulating insulin secretion and glucose metabolism |
| DK2146961T3 (da) | 2007-04-12 | 2014-04-28 | Ivax Int Gmbh | N-oxid- og/eller di-N-oxidderivater af dopaminreceptorstabilisatorer/modulatorer udvisende forbedrede cardiovaskulære bivirkningsprofiler |
| WO2008133884A2 (en) * | 2007-04-23 | 2008-11-06 | Combinatorx, Incorporated | Methods and compositions for the treatment of neurodegenerative disorders |
| US20100197712A1 (en) * | 2007-06-18 | 2010-08-05 | Arvid Carlsson | Use of dopamine stabilizers |
| GB2462611A (en) * | 2008-08-12 | 2010-02-17 | Cambridge Lab | Pharmaceutical composition comprising tetrabenazine |
| WO2011019956A2 (en) * | 2009-08-12 | 2011-02-17 | Biovail Laboratories International (Barbados) S.R.L. | Pharmaceutical compositions |
| BRPI0920927A2 (pt) | 2008-11-13 | 2019-09-24 | Link Medicine Corp | derivados de azaquinolinona e usos dos mesmos |
| JP2012529432A (ja) * | 2009-06-05 | 2012-11-22 | リンク・メディスン・コーポレーション | アミノピロリジノン誘導体及びその使用 |
| KR101401386B1 (ko) | 2009-07-29 | 2014-05-29 | 주식회사 녹십자 | 신경보호제로서의 (+)-3-하이드록시모르피난 유도체 |
| US20110206782A1 (en) | 2010-02-24 | 2011-08-25 | Auspex Pharmaceuticals, Inc. | Piperidine modulators of dopamine receptor |
| WO2011107583A1 (en) | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
| US20130203886A1 (en) | 2010-03-05 | 2013-08-08 | Nileshkumar Prakash Kukalyekar | Process for the production of an uhmwpe article |
| US20120003330A1 (en) * | 2010-06-01 | 2012-01-05 | Auspex Pharmaceuticals, Inc. | Benzoquinolone inhibitors of vmat2 |
| CN103080343A (zh) | 2010-07-02 | 2013-05-01 | Skf公司 | 机械部件和用于表面硬化的方法 |
| BR112013005125A2 (pt) | 2010-09-03 | 2016-08-16 | Ivax Int Gmbh | deuterados análogos dos pridopidine úteis como estabilizadores dopaminérgicos |
| CA2847736A1 (en) | 2011-09-07 | 2013-03-14 | IVAX International GmbH | A new polymorphic form of pridopidine hydrochloride |
| MX347209B (es) | 2011-12-08 | 2017-04-19 | Teva Pharmaceuticals Int Gmbh | La sal de bromhidrato de pridopidina. |
-
2013
- 2013-04-03 US US13/856,254 patent/US20130267552A1/en not_active Abandoned
- 2013-04-03 WO PCT/US2013/035124 patent/WO2013152105A1/en not_active Ceased
- 2013-04-03 KR KR1020147030277A patent/KR20150013476A/ko not_active Withdrawn
- 2013-04-03 HK HK15106790.2A patent/HK1206297A1/xx unknown
- 2013-04-03 MX MX2014011971A patent/MX2014011971A/es unknown
- 2013-04-03 CN CN201380018981.6A patent/CN104470585A/zh active Pending
- 2013-04-03 NZ NZ630560A patent/NZ630560A/en not_active IP Right Cessation
- 2013-04-03 EP EP13772325.0A patent/EP2844346B1/en active Active
- 2013-04-03 CA CA 2869145 patent/CA2869145A1/en not_active Abandoned
- 2013-04-03 AU AU2013243461A patent/AU2013243461A1/en not_active Abandoned
- 2013-04-03 JP JP2015504706A patent/JP6177875B2/ja active Active
- 2013-04-03 BR BR112014024672A patent/BR112014024672A8/pt active Search and Examination
- 2013-04-03 EA EA201491819A patent/EA027748B1/ru active IP Right Revival
- 2013-04-03 ES ES13772325T patent/ES2776678T3/es active Active
-
2014
- 2014-09-23 IL IL234831A patent/IL234831B/en active IP Right Grant
- 2014-10-23 ZA ZA2014/07726A patent/ZA201407726B/en unknown
-
2017
- 2017-06-02 US US15/612,779 patent/US20170266170A1/en not_active Abandoned
-
2018
- 2018-11-28 US US16/203,182 patent/US11207308B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2844346A1 (en) | 2015-03-11 |
| AU2013243461A1 (en) | 2014-11-06 |
| IL234831B (en) | 2020-10-29 |
| EP2844346A4 (en) | 2015-11-18 |
| EA201491819A1 (ru) | 2015-04-30 |
| WO2013152105A1 (en) | 2013-10-10 |
| JP6177875B2 (ja) | 2017-08-09 |
| JP2015515475A (ja) | 2015-05-28 |
| IL234831A0 (en) | 2014-12-31 |
| EP2844346B1 (en) | 2020-01-01 |
| US20170266170A1 (en) | 2017-09-21 |
| EA027748B1 (ru) | 2017-08-31 |
| NZ630560A (en) | 2016-11-25 |
| HK1206297A1 (en) | 2016-01-08 |
| US11207308B2 (en) | 2021-12-28 |
| KR20150013476A (ko) | 2015-02-05 |
| MX2014011971A (es) | 2015-01-16 |
| ZA201407726B (en) | 2016-05-25 |
| BR112014024672A2 (enExample) | 2017-06-20 |
| ES2776678T3 (es) | 2020-07-31 |
| CN104470585A (zh) | 2015-03-25 |
| US20130267552A1 (en) | 2013-10-10 |
| BR112014024672A8 (pt) | 2018-04-03 |
| US20200000785A1 (en) | 2020-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11207308B2 (en) | Pharmaceutical compositions for combination therapy | |
| EP1701725B1 (en) | Compositions comprising flupirtine and an opioid for use in the treatment of neuropathic pain | |
| KR20250029267A (ko) | 과다운동성 운동 장애의 치료를 위한 vmat2 억제제 | |
| US20120129834A1 (en) | Serotonin receptor antagonists for use in the treatment of huntington's disease | |
| KR20060032598A (ko) | 세로토닌 재흡수 억제제 및 아고멜라틴의 조합 | |
| ES2769780T3 (es) | Tratamientos novedosos para los trastornos de atención y cognitivos y para la demencia asociada a un trastorno neurodegenerativo | |
| JP2016512561A (ja) | オピオイド／トール様受容体４アンタゴニスト、そのデキストロエナンチオマーを含む、痛みを軽減するための組成物、及びそのための使用方法 | |
| KR20250059489A (ko) | 조현병 및 기타 신경정신장애 및 신경학적 장애의 치료를 위한 환각물질 포함 조합물 | |
| US7786126B2 (en) | Combination preparations comprising SLV308 and a dopamine agonist | |
| TW201345528A (zh) | 用於組合療法之醫藥組合物 | |
| Waters et al. | Co-administration of the dopaminergic stabilizer pridopidine and tetrabenazine in rats | |
| Mehlisch | Double‐Blind, Single‐Dose Comparison of Bromfenac Sodium, Tramadol, and Placebo after Oral Surgery | |
| Picco et al. | Serotonin syndrome in advanced cancer patient treated with tramadol and antidepressants | |
| RU2779202C2 (ru) | Комбинация, содержащая декановую кислоту, для лечения эпилепсии | |
| EP2035002A1 (en) | Combination preparations comprising slv308 and a l-dopa | |
| JP2025087929A (ja) | うつ病および／またはうつ状態の治療および／または予防用医薬 | |
| CN108778264A (zh) | 用于治疗疼痛、炎症、炎性疾病、免疫或自身免疫疾病和肿瘤生长的单独的或与类固醇组合的(r)-卡比多巴 | |
| AEs et al. | DOSING AND USE | |
| Millar | Invega: effective schizophrenia treatment | |
| Wang | Advances in the management of oxaliplatin-induced neuropathy: focus on glutamine and using pharmacogenomics to predict the effectiveness of opioid drugs | |
| Range et al. | DONEPEZIL (continued) | |
| From | Selective serotonin receptor agonists. Serotonin receptor blockers | |
| Range et al. | DOSING AND USE | |
| Nam et al. | P. 2. a. 027 Association between tryptophan hydroxylase 2 gene and the personality traits of novelty seeking and harm avoidance | |
| HK1135017A (en) | Combination preparations comprising slv308 and a l-dopa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20190403 |